MARKET

BCDAW

BCDAW

BIOCARDIA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.800
+0.020
+1.11%
Closed 16:00 01/20 EST
OPEN
1.700
PREV CLOSE
1.780
HIGH
1.800
LOW
1.700
VOLUME
2.50K
TURNOVER
--
52 WEEK HIGH
3.500
52 WEEK LOW
0.5150
MARKET CAP
2.03M
P/E (TTM)
-0.9200
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed
BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase II...
GlobeNewswire · 12/17/2020 13:30
BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery
Technology May Enable Same-Day Outpatient Cell Therapy ProceduresSAN CARLOS, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of U.S. Patent No: 10,780,248
GlobeNewswire · 09/29/2020 12:00
BRIEF-BioCardia Says Submitted Detailed Response FDA Related To Investigational New Drug Application For BCDA-03
* BIOCARDIA INC - SUBMITTED DETAILED RESPONSE FDA RELATED TO INVESTIGATIONAL NEW DRUG APPLICATION FOR BCDA-03
Reuters · 07/07/2020 12:22
BRIEF-Biocardia Reports Cardiamp Heart Failure Pivotal Trial Continues
* BIOCARDIA ANNOUNCES CARDIAMP HEART FAILURE PIVOTAL TRIAL CONTINUES WITH FIRST PATIENT RANDOMIZED IN COVID-19 ERA
Reuters · 07/01/2020 12:16
BRIEF-Biocardia Announces CardiAMP Heart Failure Pivotal Trial Continues With First Patient Randomized In COVID-19 Era
* BIOCARDIA ANNOUNCES CARDIAMP HEART FAILURE PIVOTAL TRIAL CONTINUES WITH FIRST PATIENT RANDOMIZED IN COVID-19 ERA Source text for Eikon: Further company coverage:
Reuters · 06/29/2020 12:32
BRIEF-BioCardia Announces Pricing Of $10 Mln Public Offering
* BIOCARDIA INC - PRICING OF ITS PUBLIC OFFERING OF 4.8 MILLION SHARES OF COMMON STOCK AT A PRICE TO PUBLIC OF $2.10 PER SHARE Source text for Eikon: Further company coverage:
Reuters · 06/17/2020 12:40
BRIEF-BioCardia Files For Offering Of 2.4 Mln Shares Of Common Stock
* BIOCARDIA INC FILES FOR OFFERING OF 2.4 MILLION SHARES OF COMMON STOCK - SEC FILING Source: https://bit.ly/2X2aS59 Further company coverage:
Reuters · 05/26/2020 10:07
BRIEF-Biocardia Reports Q1 Net Loss of $4.6 Million
* BIOCARDIA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Reuters · 05/15/2020 12:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCDAW. Analyze the recent business situations of BIOCARDIA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
-0.03%
Key Executives
Chairman/Independent Director
Simon Stertzer
President/Chief Executive Officer/Director
Peter Altman
Chief Financial Officer
David McClung
Vice President - Operations
Phil Pesta
Other
Henricus Duckers
Director
Krisztina Zsebo
Independent Director
Jim Allen
Independent Director
Andrew Blank
Independent Director
Fernando Fernandez
Independent Director
Richard Krasno
Independent Director
Jay Moyes
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BCDAW
BioCardia, Inc. is a clinical-stage regenerative medicine company engaged in developing therapeutics for cardiovascular diseases. The Company's therapeutic portfolio consists of the CardiAMP and CardiALLO cell therapies. The Company's lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP) and focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company's CardiALLO Cell Therapy System (CardiALLO), is an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. The Company’s products also include Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products.
More

Webull offers kinds of BioCardia Inc stock information, including NASDAQ:BCDAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCDAW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCDAW stock methods without spending real money on the virtual paper trading platform.